Sure, but we haven't even got thru the FDA. This result will only enhance the case of a successful FDA outcome, it won't change anything at the clinical/patient level.
In the world of biotech and medical devices though, this outcome should be significantly value accretive, that is, the technology will be worth a whole lot more on a succesful trial.
How much more, who knows? But you'd be a bit disappointed if it didn't punch thru the IPO price.
General Investor Information EBR Systems, page-42
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.025(2.39%) |
Mkt cap ! $329.6M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.04 | $120.6K | 113.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 170 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 2700 | 1 |
View Market Depth
| Last trade - 15.46pm 09/08/2024 (20 minute delay) ? |
| EBR (ASX) Chart |